Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine - Pharmacology & Pharmacy

PP > Vol.10 No.1, January 2019

Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine ()

HTML XML

Download as PDF (Size: 4251KB) PP. 1-10

DOI: 10.4236/pp.2019.101001 2,113 Downloads 4,975 Views Citations

Author(s)

Robert B. Raffa^1,2,3, Joseph V. Pergolizzi^1,4, Robert Taylor⁴, Robert P. James⁵, Mark Pirner⁵

Affiliation(s)

¹Neumentum, Inc., Palo Alto, CA, USA.
²University of Arizona College of Pharmacy, Tucson, AZ, USA.
³Temple University School of Pharmacy, Philadelphia, PA, USA.
⁴NEMA Research, Inc., Naples, FL, USA.
⁵US WorldMeds, LLC, Louisville, KY, USAs.

ABSTRACT

Lucemyra? (lofexidine hydrochloride) has recently been approved by the US FDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Lofexidine is an alpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidine differ in advantageous ways from the classical alpha-2 adrenoceptor agonist clonidine. In the present study, we measured the receptor binding profile of lofexidine and clonidine in an effort to gain an insight into the clinical difference(s).

KEYWORDS

Lofexidine, Clonidine, Opioid Withdrawal, Receptor Affinity, Alpha-2 Agonist

Share and Cite:

Raffa, R. , Pergolizzi, J. , Taylor, R. , James, R. and Pirner, M. (2019) Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine. Pharmacology & Pharmacy, 10, 1-10. doi: 10.4236/pp.2019.101001.

Journals Menu

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals Menu

Home

About SCIRP

Service

Policies